Eloxatin (oxaliplatin)

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: ______________________________ **Date**: ________________________________
Patient's ID: ________________________________ **Patient's Date of Birth:** ________________
Physician's Name: ____
Specialty: __________________________________ **NPI#:** _________________________________
Physician Office Telephone: __________________ **Physician Office Fax:** ___________________

<u>Referring</u> Provider Info: ❑ Same as Requesting Provider
Name: ____ **NPI#:** ______________________________
Fax: _________________________ **Phone:** ______________________

<u>Rendering</u> Provider Info: ❑ Same as Referring Provider ❑ Same as Requesting Provider
Name: ____ **NPI#:** ______________________________
Fax: _________________________ **Phone:** ______________________

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

<u>Required Demographic Information:</u>

Patient Weight: __________________________*kg*

*Patient Height:*___________________________*cm*

Please indicate the place of service for the requested drug:

❑ Ambulatory Surgical *❑ Home* *❑ Off Campus Outpatient Hospital*
❑ On Campus Outpatient Hospital *❑ Office* *❑ Pharmacy*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oxaliplatin SGM – 12/2020.

Criteria Questions:

1. What is the prescribed medication? ❑ Eloxatin ❑ Oxaliplatin (generic) ❑ Other ______________________

2. What is the diagnosis?
   ❑ Colorectal cancer (including appendiceal adenocarcinoma and colon and rectal cancers)
   ❑ Pancreatic adenocarcinoma
   ❑ Esophageal or esophagogastric junction cancer
   ❑ Gastric cancer
   ❑ Hepatobiliary cancer (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer)
   ❑ Neuroendocrine and adrenal tumor (including neuroendocrine tumors of the pancreas and poorly differentiated [high grade]/large or small cell disease)
   ❑ Occult primary (cancer of unknown primary)
   ❑ Epithelial ovarian cancer
   ❑ Fallopian tube cancer
   ❑ Primary peritoneal cancer
   ❑ Mucinous carcinoma
   ❑ Testicular cancer
   ❑ Bladder cancer (including non-urothelial and urothelial cancer with variant histology)
   ❑ Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL)
   ❑ Anal carcinoma
   ❑ B-cell lymphoma (including follicular lymphoma [grade 1-2], histologic transformation of nodal marginal zone lymphoma to diffuse large B-Cell lymphoma, mantle cell lymphoma, diffuse large B-Cell lymphoma, high-grade B-Cell lymphomas, AIDS-Related B-Cell lymphomas, and post-transplant lymphoproliferative disorders)
   ❑ Primary cutaneous lymphoma (including mycosis fungoides/Sezary syndrome and primary cutaneous CD30+ T-Cell lymphoproliferative disorders)
   ❑ T-cell lymphoma (including peripheral T-Cell lymphomas, adult T-Cell leukemia/lymphoma, hepatosplenic gamma-delta T-Cell lymphoma, and extranodal NKT/T-Cell lymphoma, nasal type)
   ❑ Classic Hodgkin lymphoma
   ❑ Small bowel adenocarcinoma
   ❑ Other ____

3. What is the ICD-10 code? ________________

4. Is this request for continuation of therapy with the requested medication?
   ❑ Yes ❑ No *If No, skip to diagnosis section*

5. Is there evidence of unacceptable toxicity or disease progression on the current regimen?
   ❑ Yes ❑ No *No further questions*

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, or Anal Carcinoma

6. What is the clinical setting in which the requested medication will be used?
   ❑ Persistent disease
   ❑ Recurrent disease
   ❑ Metastatic disease
   ❑ None of the above

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oxaliplatin SGM – 12/2020.